Faculty present the progression-free survival findings from CABINET across both cohorts, emphasizing the encouraging and practice-changing results in a heavily pretreated population. In the pancreatic neuroendocrine tumor cohort, median progression-free survival exceeded 13 months with cabozantinib versus roughly 4 months with placebo.
ADVERTISEMENT
ADVERTISEMENT
2026 Copyright © News-Matic.com. All Rights Reserved
